Literature DB >> 3090875

Serum electrolyte patterns in end-stage renal disease.

R Wallia, A Greenberg, B Piraino, R Mitro, J B Puschett.   

Abstract

The charts of 70 successive patients presenting for dialysis therapy for end-stage renal disease (ESRD) were evaluated for their serum electrolyte values. The "classical" pattern of low total CO2 (tCO2), elevated anion gap ("delta"), and normal chloride was found in a minority of patients (14 of 70, or 20%). Hyperchloremia was noted in 46%; in 21 patients (30%), this was associated with a normal delta and in 11 (16%), hyperchloremia was accompanied by an elevated delta. Fourteen patients (20%), most with diabetic nephropathy, had normal serum electrolytes. Patients with chronic glomerulonephritis had a hyperchloremic pattern as often as not, and two of four patients with interstitial nephritis demonstrated hyperchloremia without an elevated delta. We conclude that the previously held thesis that hyperchloremia is a rare or absent finding by the time renal failure progresses to ESRD is no longer tenable. Furthermore, a significant minority of ESRD patients may require the initiation of dialysis at a time when their serum electrolytes are still normal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090875     DOI: 10.1016/s0272-6386(86)80119-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

Review 1.  Differential diagnosis of nongap metabolic acidosis: value of a systematic approach.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  Anion gap predicts early mortality after starting hemodialysis in the elderly.

Authors:  Yohei Arai; Hiroyuki Tanaka; Shingo Shioji; Emi Sakamoto; Isao Kondo; Minami Suzuki; Daisuke Katagiri; Manami Tada; Fumihiko Hinoshita
Journal:  Clin Exp Nephrol       Date:  2020-01-27       Impact factor: 2.801

3.  Elevated serum anion gap in adults with moderate chronic kidney disease increases risk for progression to end-stage renal disease.

Authors:  Tanushree Banerjee; Deidra C Crews; Donald E Wesson; Charles E McCulloch; Kirsten L Johansen; Sharon Saydah; Nilka Rios Burrows; Rajiv Saran; Brenda Gillespie; Jennifer Bragg-Gresham; Neil R Powe
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-25

4.  Gap acidosis except lactic acidosis develops and progresses during chronic kidney disease stage G5.

Authors:  Masayuki Tanemoto
Journal:  Clin Exp Nephrol       Date:  2019-05-06       Impact factor: 2.801

5.  Association of pre-ESKD hyponatremia with post-ESKD outcomes among incident ESKD patients.

Authors:  Maria V Marroquin; John Sy; Carola-Ellen Kleine; Justin Oveyssi; Jui-Ting Hsiung; Christina Park; Melissa Soohoo; Csaba P Kovesdy; Connie M Rhee; Elani Streja; Kamyar Kalantar-Zadeh; Ekamol Tantisattamo
Journal:  Nephrol Dial Transplant       Date:  2022-01-25       Impact factor: 7.186

Review 6.  Consequences and therapy of the metabolic acidosis of chronic kidney disease.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

7.  Cochlear Implantation in a Patient with Failed Renal Transplant: A Case Report.

Authors:  K S Raghavendra; Sunil Narayan Dutt; S G Maneesh; Suhel Hasan; Sumit Kumar Gaur; Apurva Kumar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-11-13

8.  The serum anion gap is altered in early kidney disease and associates with mortality.

Authors:  Matthew K Abramowitz; Thomas H Hostetter; Michal L Melamed
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

Review 9.  Sodium bicarbonate therapy in patients with metabolic acidosis.

Authors:  María M Adeva-Andany; Carlos Fernández-Fernández; David Mouriño-Bayolo; Elvira Castro-Quintela; Alberto Domínguez-Montero
Journal:  ScientificWorldJournal       Date:  2014-10-21

10.  Metabolic acidosis and the progression of chronic kidney disease.

Authors:  Wei Chen; Matthew K Abramowitz
Journal:  BMC Nephrol       Date:  2014-04-03       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.